mirtazapine has been researched along with Disease Models, Animal in 34 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mirtazapine (MIRT) is a multi-target antidepressant used in treatment of severe depression with promising efficacy, but also with important side effects, mainly sedation and weight gain." | 8.12 | Lipoic acid prevents mirtazapine-induced weight gain in mice without impairs its antidepressant-like action in a neuroendocrine model of depression. ( Chaves Filho, AJM; Cunha, NL; De Oliveira, GMF; Gadelha Filho, CVJ; Jucá, PM; Macedo, DS; Oliveira, TQ; Soares, MVR; Vasconcelos, SMM; Viana, GA; Vieira, CFX, 2022) |
| "Therefore, the findings support the use of mirtazapine as a potentially effective therapy to reduce anxiety and depressive-like behavior during cocaine withdrawal." | 7.91 | Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal. ( Barbosa Méndez, S; Salazar-Juárez, A, 2019) |
| "The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia." | 7.88 | Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. ( Lorenc-Koci, E; Rogóż, Z; Wąsik, A, 2018) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 7.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "The effects of acute systemic administration of duloxetine, amitriptyline, mirtazapine and fluoxetine were compared in experimental models of gastric ulcer in rats." | 7.78 | Evaluation of the anti-ulcerogenic activity of the antidepressants duloxetine, amitriptyline, fluoxetine and mirtazapine in different models of experimental gastric ulcer in rats. ( Fan, DS; Guo, L; Ji, CX; Li, W; Liang, ZL; Xu, RM; Zhang, JJ, 2012) |
| "To investigate whether the tetracyclic antidepressant mirtazapine has a pain-suppressing effect in healthy animals." | 7.77 | The acute effects of mirtazapine on pain related behavior in healthy animals. ( Baydemir, C; Dogan, AE; Erol, K; Kilic, FS, 2011) |
| " We have investigated the effects of mirtazapine on pentylenetetrazole (PTZ)- and maximal electroconvulsive shock (MES)-induced seizures in mice." | 7.74 | Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice. ( Kayir, H; Sezer, Z; Uzbay, TI; Yilmaz, I, 2007) |
| "The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain." | 7.73 | Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. ( Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD, 2005) |
| "Mirtazapine is a novel antidepressant and a potent 5-HT(2) receptor antagonistic." | 5.36 | Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Yoshino, T, 2010) |
| " The present study was designed to explore the effects and most appropriate dosage of mirtazapine in treating neuropathic pain and its possible neuroimmune mechanisms." | 5.35 | Repeated administration of mirtazapine inhibits development of hyperalgesia/allodynia and activation of NF-kappaB in a rat model of neuropathic pain. ( Feng, X; Hu, Y; Song, J; Wei, X; Xu, J; Zhu, J, 2008) |
| "Mirtazapine (MIRT) is a multi-target antidepressant used in treatment of severe depression with promising efficacy, but also with important side effects, mainly sedation and weight gain." | 4.12 | Lipoic acid prevents mirtazapine-induced weight gain in mice without impairs its antidepressant-like action in a neuroendocrine model of depression. ( Chaves Filho, AJM; Cunha, NL; De Oliveira, GMF; Gadelha Filho, CVJ; Jucá, PM; Macedo, DS; Oliveira, TQ; Soares, MVR; Vasconcelos, SMM; Viana, GA; Vieira, CFX, 2022) |
| "Therefore, the findings support the use of mirtazapine as a potentially effective therapy to reduce anxiety and depressive-like behavior during cocaine withdrawal." | 3.91 | Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal. ( Barbosa Méndez, S; Salazar-Juárez, A, 2019) |
| "The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia." | 3.88 | Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. ( Lorenc-Koci, E; Rogóż, Z; Wąsik, A, 2018) |
| "Several clinical reports have postulated a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants in treatment-resistant depression." | 3.78 | Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. ( Gądek-Michalska, A; Kabziński, M; Rachwalska, P; Rogóż, Z; Sadaj, W, 2012) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 3.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "The effects of acute systemic administration of duloxetine, amitriptyline, mirtazapine and fluoxetine were compared in experimental models of gastric ulcer in rats." | 3.78 | Evaluation of the anti-ulcerogenic activity of the antidepressants duloxetine, amitriptyline, fluoxetine and mirtazapine in different models of experimental gastric ulcer in rats. ( Fan, DS; Guo, L; Ji, CX; Li, W; Liang, ZL; Xu, RM; Zhang, JJ, 2012) |
| "The purpose of this study was to elucidate the mechanism underlying the clinical efficacy of mirtazapine-perospirone combination therapy for treatment-resistant depression in a rat model." | 3.77 | Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation. ( Morita, M; Nakayama, K, 2011) |
| "To investigate whether the tetracyclic antidepressant mirtazapine has a pain-suppressing effect in healthy animals." | 3.77 | The acute effects of mirtazapine on pain related behavior in healthy animals. ( Baydemir, C; Dogan, AE; Erol, K; Kilic, FS, 2011) |
| " We have investigated the effects of mirtazapine on pentylenetetrazole (PTZ)- and maximal electroconvulsive shock (MES)-induced seizures in mice." | 3.74 | Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice. ( Kayir, H; Sezer, Z; Uzbay, TI; Yilmaz, I, 2007) |
| "The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain." | 3.73 | Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. ( Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD, 2005) |
| "Mirtazapine (MRT) is a well-known antidepressant that was proven to have anti-inflammatory activity; however, to date, its role has not been investigated in UC." | 1.62 | Protective effect of mirtazapine against acetic acid-induced ulcerative colitis in rats: Role of NLRP3 inflammasome pathway. ( Abdel-Gaber, SA; Gad, AA; Hafez, HM; Ibrahim, MA; Mohammed Naguib Abdel Hafez, S; Yehia Abdelzaher, W, 2021) |
| "Mirtazapine is an atypical antidepressant with antagonist activity for serotonin and histamine receptors." | 1.56 | The Antidepressant Mirtazapine Activates Hepatic Macrophages, Facilitating Pathogen Clearance While Limiting Tissue Damage in Mice. ( Almishri, W; Davis, RP; Jenne, CN; Swain, MG, 2020) |
| " This study aimed to investigate the effects of mirtazapine (MIRT) alone and combined with alpha-lipoic acid (ALA) against corticosterone (CORT) induced behavioral and oxidative alterations." | 1.46 | Brain antioxidant effect of mirtazapine and reversal of sedation by its combination with alpha-lipoic acid in a model of depression induced by corticosterone. ( de Oliveira, AA; de Sousa, CNS; de Sousa, LC; Honório Júnior, JER; Macedo, D; Maes, M; Medeiros, IDS; Oliveira, TQ; Patrocínio, CFV; Vasconcelos, GS; Vasconcelos, SMM, 2017) |
| " Time-course data for the dose-response effects were analyzed using two-way analysis of variance and the posthoc Tukey-Kramer multiple-comparison test." | 1.40 | Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats. ( Hashimoto, R; Hosokawa, K; Mashimo, T; Nakae, A; Nakai, K, 2014) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant." | 1.40 | Prokinetic effects of mirtazapine on gastrointestinal transit. ( Chen, JD; Lei, Y; Song, J; Xu, X; Yin, J, 2014) |
| "Mirtazapine was also reported to increase dopamine release in the cortical neurons with 5-HT dependent manner." | 1.40 | Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease. ( Fukano, T; Kadoguchi, N; Kasahara, J; Okabe, S; Shono, M; Tanabe, A; Yamamura, Y; Yokoyama, H, 2014) |
| "In a model of neuropathic pain, sciatic nerve ligation caused a marked decrease in the latency of paw withdrawal in response to a thermal stimulus only on the ipsilateral side." | 1.38 | Effects of mirtazapine on sleep disturbance under neuropathic pain-like state. ( Enomoto, T; Hirayama, S; Horiuchi, H; Ikegami, D; Inada, E; Iseki, M; Nagase, H; Nakahara, K; Narita, M; Sakai, H; Suzuki, T; Torigoe, K; Yamashita, A; Yanase, M, 2012) |
| "Pretreatment with mirtazapine 24h prior to the CPP test had no effect on CPP expression." | 1.38 | The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization. ( Graves, SM; Napier, TC; Persons, AL; Riddle, JL, 2012) |
| "Mirtazapine is a novel antidepressant and a potent 5-HT(2A) receptor antagonist." | 1.37 | The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. ( Iwamura, T; Kasai, M; Kato, S; Nisijima, K; Shioda, K; Yoshino, T, 2011) |
| "Mirtazapine is a novel antidepressant and a potent 5-HT(2) receptor antagonistic." | 1.36 | Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Yoshino, T, 2010) |
| " The present study was designed to explore the effects and most appropriate dosage of mirtazapine in treating neuropathic pain and its possible neuroimmune mechanisms." | 1.35 | Repeated administration of mirtazapine inhibits development of hyperalgesia/allodynia and activation of NF-kappaB in a rat model of neuropathic pain. ( Feng, X; Hu, Y; Song, J; Wei, X; Xu, J; Zhu, J, 2008) |
| "Mirtazapine is a widely used antidepressant and the aim of this study was to further investigate its antidepressant activity in rats." | 1.33 | Study of mirtazapine antidepressant effects in rats. ( Cassanelli, A; Gambarana, C; Raone, A; Rauggi, R; Tagliamonte, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (17.65) | 29.6817 |
| 2010's | 20 (58.82) | 24.3611 |
| 2020's | 8 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Hafez, HM | 1 |
| Ibrahim, MA | 1 |
| Yehia Abdelzaher, W | 1 |
| Gad, AA | 1 |
| Mohammed Naguib Abdel Hafez, S | 1 |
| Abdel-Gaber, SA | 1 |
| Oliveira, TQ | 2 |
| Chaves Filho, AJM | 1 |
| Jucá, PM | 1 |
| Soares, MVR | 1 |
| Cunha, NL | 1 |
| Vieira, CFX | 1 |
| Gadelha Filho, CVJ | 1 |
| Viana, GA | 1 |
| De Oliveira, GMF | 1 |
| Macedo, DS | 1 |
| Vasconcelos, SMM | 2 |
| Flores Gutiérrez, J | 2 |
| Natali, G | 2 |
| Giorgi, J | 1 |
| De Leonibus, E | 1 |
| Tongiorgi, E | 2 |
| Surowka, P | 1 |
| Noworyta, K | 1 |
| Cieslik, A | 1 |
| Rygula, R | 1 |
| Schreiber, S | 1 |
| Pick, CG | 1 |
| De Felice, C | 1 |
| Leoncini, S | 1 |
| Signorini, C | 1 |
| Hayek, J | 1 |
| Davis, RP | 1 |
| Almishri, W | 2 |
| Jenne, CN | 1 |
| Swain, MG | 2 |
| de Sousa, CNS | 1 |
| Vasconcelos, GS | 1 |
| de Sousa, LC | 1 |
| de Oliveira, AA | 1 |
| Patrocínio, CFV | 1 |
| Medeiros, IDS | 1 |
| Honório Júnior, JER | 1 |
| Maes, M | 1 |
| Macedo, D | 1 |
| Rogóż, Z | 3 |
| Wąsik, A | 1 |
| Lorenc-Koci, E | 1 |
| Bektur, E | 1 |
| Şahin, E | 1 |
| Ceyhan, E | 1 |
| Donmez, DB | 1 |
| Canbek, M | 1 |
| Baycu, C | 1 |
| Can, OD | 1 |
| Barbosa Méndez, S | 1 |
| Salazar-Juárez, A | 1 |
| Shaheen, AA | 1 |
| Sharkey, KA | 1 |
| Kabziński, M | 1 |
| Sadaj, W | 1 |
| Rachwalska, P | 1 |
| Gądek-Michalska, A | 1 |
| Nakai, K | 1 |
| Nakae, A | 1 |
| Hashimoto, R | 1 |
| Mashimo, T | 1 |
| Hosokawa, K | 1 |
| Yin, J | 2 |
| Song, J | 2 |
| Lei, Y | 1 |
| Xu, X | 1 |
| Chen, JD | 2 |
| Kadoguchi, N | 1 |
| Okabe, S | 1 |
| Yamamura, Y | 1 |
| Shono, M | 1 |
| Fukano, T | 1 |
| Tanabe, A | 1 |
| Yokoyama, H | 1 |
| Kasahara, J | 1 |
| Kálmán, J | 1 |
| Wang, W | 1 |
| Winston, JH | 1 |
| Zhang, R | 1 |
| Kotsovolou, O | 1 |
| Ingelman-Sundberg, M | 1 |
| Lang, MA | 1 |
| Marselos, M | 1 |
| Overstreet, DH | 1 |
| Papadopoulou-Daifoti, Z | 1 |
| Johanson, I | 1 |
| Fotopoulos, A | 1 |
| Konstandi, M | 1 |
| Shioda, K | 2 |
| Nisijima, K | 2 |
| Yoshino, T | 2 |
| Kato, S | 2 |
| Morita, M | 1 |
| Nakayama, K | 1 |
| Kasai, M | 1 |
| Iwamura, T | 1 |
| Kilic, FS | 1 |
| Dogan, AE | 1 |
| Baydemir, C | 1 |
| Erol, K | 1 |
| Enomoto, T | 1 |
| Yamashita, A | 1 |
| Torigoe, K | 1 |
| Horiuchi, H | 1 |
| Hirayama, S | 1 |
| Nakahara, K | 1 |
| Yanase, M | 1 |
| Sakai, H | 1 |
| Ikegami, D | 1 |
| Nagase, H | 1 |
| Suzuki, T | 1 |
| Iseki, M | 1 |
| Inada, E | 1 |
| Narita, M | 1 |
| Ji, CX | 1 |
| Fan, DS | 1 |
| Guo, L | 1 |
| Liang, ZL | 1 |
| Xu, RM | 1 |
| Zhang, JJ | 1 |
| Sener, MT | 1 |
| Sener, E | 1 |
| Tok, A | 1 |
| Polat, B | 1 |
| Cinar, I | 1 |
| Polat, H | 1 |
| Akcay, F | 1 |
| Suleyman, H | 1 |
| Graves, SM | 1 |
| Persons, AL | 1 |
| Riddle, JL | 1 |
| Napier, TC | 1 |
| Bomholt, SF | 1 |
| Mikkelsen, JD | 1 |
| Blackburn-Munro, G | 1 |
| Rauggi, R | 1 |
| Cassanelli, A | 1 |
| Raone, A | 1 |
| Tagliamonte, A | 1 |
| Gambarana, C | 1 |
| Freynhagen, R | 1 |
| Vogt, J | 1 |
| Lipfert, P | 1 |
| Muth-Selbach, U | 1 |
| Yilmaz, I | 1 |
| Sezer, Z | 1 |
| Kayir, H | 1 |
| Uzbay, TI | 1 |
| Zhu, J | 1 |
| Wei, X | 1 |
| Feng, X | 1 |
| Hu, Y | 1 |
| Xu, J | 1 |
1 review available for mirtazapine and Disease Models, Animal
| Article | Year |
|---|---|
[Genomical and metabolomical abnormalities in Alzheimer disease and in experimental models].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antidepressive Agents; Apolipoprotein E4 | 2008 |
1 trial available for mirtazapine and Disease Models, Animal
| Article | Year |
|---|---|
Protective role of mirtazapine in adult female Mecp2
Topics: Animals; Disease Models, Animal; Female; Humans; Methyl-CpG-Binding Protein 2; Mice; Mirtazapine; Re | 2020 |
32 other studies available for mirtazapine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Protective effect of mirtazapine against acetic acid-induced ulcerative colitis in rats: Role of NLRP3 inflammasome pathway.
Topics: Acetic Acid; Animals; Colitis, Ulcerative; Colon; Disease Models, Animal; Humans; Inflammasomes; Int | 2021 |
Lipoic acid prevents mirtazapine-induced weight gain in mice without impairs its antidepressant-like action in a neuroendocrine model of depression.
Topics: Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Cognitive Dysfunction; Corticosteron | 2022 |
Mirtazapine treatment in a young female mouse model of Rett syndrome identifies time windows for the rescue of early phenotypes.
Topics: Adolescent; Adult; Animals; Antidepressive Agents; Body Weight; Disease Models, Animal; Female; Huma | 2022 |
Trait sensitivity to negative feedback determines the effects of chronic stress and chronic mirtazapine treatment on anxiety and stress-coping strategies in rats.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Anxiety; Disease Models, Animal; Feedback | 2022 |
Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep?
Topics: Analgesics; Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Disease Models, Animal; | 2020 |
The Antidepressant Mirtazapine Activates Hepatic Macrophages, Facilitating Pathogen Clearance While Limiting Tissue Damage in Mice.
Topics: Animals; Antidepressive Agents; Disease Models, Animal; Host-Pathogen Interactions; Kupffer Cells; L | 2020 |
Brain antioxidant effect of mirtazapine and reversal of sedation by its combination with alpha-lipoic acid in a model of depression induced by corticosterone.
Topics: Animals; Antidepressive Agents, Tricyclic; Antioxidants; Brain; Brain-Derived Neurotrophic Factor; C | 2017 |
Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Disease Models, Anim | 2018 |
Beneficial effect of mirtazapine on diabetes-induced hyperalgesia: involvement of TRPV1 and ASIC1 channels in the spinal cord and dorsal root ganglion.
Topics: Acid Sensing Ion Channels; Animals; Capsaicin; Diabetes Mellitus, Experimental; Disease Models, Anim | 2019 |
Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cocaine; Depression; Disease Models, Anim | 2019 |
The Antidepressant Mirtazapine Inhibits Hepatic Innate Immune Networks to Attenuate Immune-Mediated Liver Injury in Mice.
Topics: Animals; Antidepressive Agents; Biomarkers; CD4-Positive T-Lymphocytes; Concanavalin A; Cytokines; D | 2019 |
Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic A | 2012 |
Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.
Topics: Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Dextroamphetamine; Disease Models, An | 2012 |
Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats.
Topics: Adrenergic alpha-Antagonists; Amines; Analgesics; Animals; Cranial Nerve Injuries; Cyclohexanecarbox | 2014 |
Prokinetic effects of mirtazapine on gastrointestinal transit.
Topics: Administration, Oral; Animals; Antidepressive Agents, Tricyclic; Colon; Disease Models, Animal; Dogs | 2014 |
Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Brain; Disease Models, Animal; Feasibility Studies; Male; | 2014 |
Ameliorating effects of mirtazapine on visceral hypersensitivity in rats with neonatal colon sensitivity.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Colon; Disease Models, Animal; Dose | 2010 |
Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Blotting, Western; Chromatography, | 2010 |
Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome.
Topics: Animals; Body Temperature; Disease Models, Animal; Fever; Male; Mianserin; Mirtazapine; Rats; Rats, | 2010 |
Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation.
Topics: Animals; Depression; Disease Models, Animal; Dopamine; Drug Resistance; Drug Synergism; Drug Therapy | 2011 |
The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Disease Models, Animal; Fever; Fluoxetine; Male; Mianseri | 2011 |
The acute effects of mirtazapine on pain related behavior in healthy animals.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Arginine; Behavior, Animal; Cyprohe | 2011 |
Effects of mirtazapine on sleep disturbance under neuropathic pain-like state.
Topics: Animals; Disease Models, Animal; Histamine H1 Antagonists; Hyperalgesia; Male; Mianserin; Mice; Mice | 2012 |
Evaluation of the anti-ulcerogenic activity of the antidepressants duloxetine, amitriptyline, fluoxetine and mirtazapine in different models of experimental gastric ulcer in rats.
Topics: Amitriptyline; Animals; Anti-Ulcer Agents; Antidepressive Agents; Disease Models, Animal; Duloxetine | 2012 |
Biochemical and histologic study of lethal cisplatin nephrotoxicity prevention by mirtazapine.
Topics: Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents; Antioxidants; Blood Urea Nitrogen; | 2012 |
The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Conditionin | 2012 |
Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.
Topics: Acute Disease; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Chronic Disease; Citalopra | 2005 |
Study of mirtazapine antidepressant effects in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Admin | 2005 |
Mirtazapine and its enantiomers differentially modulate acute thermal nociception in rats.
Topics: Afferent Pathways; Animals; Antidepressive Agents, Tricyclic; Central Nervous System; Disease Models | 2006 |
Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Chi-Square Distribution; Depressive | 2007 |
Repeated administration of mirtazapine inhibits development of hyperalgesia/allodynia and activation of NF-kappaB in a rat model of neuropathic pain.
Topics: Animals; Antidepressive Agents, Tricyclic; Brain; Cytokines; Denervation; Disease Models, Animal; Do | 2008 |